The National Cancer Institute (NCI) coordinates the United States National Cancer Program and is part of the National Institutes of Health (NIH), which is one of eleven agencies that are part of the U.S. Department of Health and Human Services. The NCI conducts and supports research, training, health information dissemination, and other activities related to the causes, prevention, diagnosis, and treatment of cancer; the supportive care of cancer patients and their families; and cancer survivorship.
The European Organisation for Research and Treatment of Cancer (EORTC) is a unique pan-European non-profit clinical cancer research organisation established in 1962 operating as an international association under Belgium law. It develops, conducts, coordinates and stimulates high-quality translational and clinical trial research to improve the survival and quality of life of cancer patients. This is achieved through the development of new drugs and other innovative approaches, and the testing of more effective therapeutic strategies, using currently approved drugs, surgery and/or radiotherapy in clinical trials conducted under the auspices of a vast network of clinical cancer researchers supported by 220 staff members based in Brussels. The EORTC has the expertise to conduct large and complex trials especially specific populations such as the older patient and rare tumours.
Cancer and Leukemia Group B is a cancer research cooperative group in the United States.
Steven Kenneth Libutti, F.A.C.S. is an American surgeon and scientist. In January 2017, he became the third permanent Director of the Rutgers Cancer Institute of New Jersey, Vice Chancellor for Cancer Programs for Rutgers Biomedical and Health Sciences and the Senior Vice President for Oncology Services for RWJBarnabas Health, the largest health system in New Jersey. He is a tenured Professor of Surgery at the Rutgers Robert Wood Johnson Medical School. Libutti's work on the study of tumor angiogenesis and the tumor microenvironment has led to novel approaches for the treatment of cancer. He is also one of the pioneers of regional and targeted cancer therapy.
Edison T. Liu, M.D. is the former president and CEO of The Jackson Laboratory, and the former director of its NCI-designated Cancer Center (2012-2021). As CEO of The Jackson Laboratory, the organization doubled revenue, faculty and personnel, expanded globally from two campuses to six, established 13 endowed chairs, and increased the institutional endowment by five-fold. He is currently a Professor and Honorary Fellow at the institution. Before joining The Jackson Laboratory, he was the founding executive director of the Genome Institute of Singapore (GIS), chairman of the board of the Health Sciences Authority, and president of the Human Genome Organization (HUGO) (2007-2013). As the executive director of the GIS, he brought the institution to international prominence as one of the most productive genomics institutions in the world.
The University of Wisconsin Carbone Cancer Center (UWCCC) is a comprehensive cancer center in Wisconsin, as designated by the National Cancer Institute (NCI), the lead federal agency for cancer research. It is an integral part of both the University of Wisconsin (UW) and the University of Wisconsin Hospital and Clinics. It is located in Madison, Wisconsin.
Larry Kwak is an American cancer researcher who works at City of Hope in Duarte, California and is the Director of the Toni Stephenson Lymphoma Center at City of Hope. Dr. Kwak formerly worked at the University of Texas MD Anderson Cancer Center. He was included on Time's list of 2010's most influential people.
Robert E. Wittes was Physician-in-Chief of Memorial Sloan-Kettering Cancer Center, from 2002 until December 31, 2012. Prior to his appointment at MSKCC, he was Deputy Director for Extramural Sciences and Director of the Division of Cancer Treatment and Diagnosis at the National Cancer Institute, where he oversaw NCI's extramural clinical and basic research programs, including the evaluation of new therapeutics, diagnostics, and translational research. Wittes is a fellow of the American College of Physicians, a member of the American Association for Cancer Research, the American Society of Clinical Oncology, and the American Federation for Medical Research. In addition to his institutional affiliations, Dr. Wittes has served as editor-in-chief of the Journal of the National Cancer Institute and Oncology. He has served on the editorial boards of Clinical Cancer Research, Current Opinion in Oncology, The American Journal of Clinical Oncology; Cancer Investigation, and The International Journal of Radiation Oncology-Biology & Physics, among others.
Professor Minesh P. Mehta, MD, FASTRO, is an American radiation oncologist and physician-scientist of Indian origin, Ugandan birth, Zambian Schooling and American Training, who contributed to the field of oncology for more than two and half decades.
Timothy Joseph Yeatman, M.D. F.A.C.S. is currently the Executive Medical Director of Oncologic Services and the Senior Medical Director for the Oncology Clinical Program at Intermountain Healthcare, serving 23 hospitals and >6000 patients across the State of Utah and Beyond. He is also Professor of Surgery at the University of Utah and a Member of the Huntsman Cancer Institute’s Cellular Response and Regulation Program. Previously, Dr Yeatman was the Director of Gibbs Cancer Center and President of Gibbs Cancer Center & Research Institute in Spartanburg, South Carolinawhere he founded the Guardian Research Network, a Nobel approach to clinical trials leveraging the entire EHR for real time database queries for trial candidates. Yeatman held numerous positions at the Moffitt Cancer Center (MCC) in Florida over the past 20 years. Yeatman served as the associate center director for clinical investigations, the associate center director for translational research, the executive vice president for translational research, professor of surgery and oncologic sciences, and section head of hepatobiliary surgery at the Moffitt Cancer Center and the University of South Florida. There he led a $100m Moffitt:Merck collaboration and co-founded a Nobel biotech company, M2Gen. He was recently named chief scientific officer for the Center for Advancement of Science in Space (CASIS), a non-profit organization appointed by Congress and funded by NASA to oversee all scientific use of the International Space Station. He continues to be NCI funded to perform colorectal cancer research in genomics and Biomarker development.
Waun Ki Hong was Professor of Medicine at The University of Texas MD Anderson Cancer Center, where he served as chairman of the Department of Thoracic/Head & Neck Medical Oncology from 1993 to 2005 and as head of the Division of Cancer Medicine from 2001 to 2014. He was also an American Cancer Society Professor and the Samsung Distinguished University Chair in Cancer Medicine emeritus.
J. William Harbour, M.D., is an American ophthalmologist, ocular oncologist and cancer researcher. He is currently Chair of the Department of Ophthalmology at the University of Texas Southwestern Medical Center in Dallas. He previously served as the vice chair and director of ocular oncology at the Bascom Palmer Eye Institute and associate director for basic science at the Sylvester Comprehensive Cancer Center of the University of Miami's Miller School of Medicine.
William G. Kaelin Jr. is an American Nobel Laureate physician-scientist. He is a professor of medicine at Harvard University and the Dana-Farber Cancer Institute. His laboratory studies tumor suppressor proteins. In 2016, Kaelin received the Albert Lasker Award for Basic Medical Research and the AACR Princess Takamatsu Award. He also won the Nobel Prize in Physiology or Medicine in 2019 along with Peter J. Ratcliffe and Gregg L. Semenza.
Elizabeth M. Jaffee is an American oncologist specializing in pancreatic cancer and immunotherapy.
David R. Gius is an American physician-scientist the Zell Family Scholar Professor, Women's Cancer Research Program director, and Vice Chair of Translational Research at Northwestern University's Feinberg School of Medicine Department of Radiation Oncology and Pharmacology. His research focuses into the mechanistic connection between aging, cellular and/or mitochondrial metabolism, and carcinogenesis focusing on the Sirtuin gene family.
Deborah E. Citrin is an American clinician-scientist researching pre-clinical and clinical testing of radiation modifiers and the mechanisms of normal tissue injury from radiation. She is a senior investigator and deputy director of the National Cancer Institute's Center for Cancer Research.
Amy K. LeBlanc is an American veterinary oncologist and biologist researching animal modeling for development of new cancer drugs and imaging agents, and identification of imaging biomarkers, development and optimization of PET imaging hardware and imaging protocols. She is a senior scientist in the molecular imaging program and director of the Comparative Oncology Program at the National Cancer Institute. LeBlanc was previously an associate professor at the University of Tennessee College of Medicine and College of Veterinary Medicine.
Jacqueline Jia-Kang Whang-Peng is a Taiwanese-American physician-scientist specialized in cytogenetics of cancer, as well as medical genetics, genetic oncology, and gene mapping. She was a researcher at the National Cancer Institute from 1960 to 1993.
Electron Kebebew, M.D., is an American surgeon, educator, and scientist. Kebebew is currently the Harry A. Oberhelman Jr. and Mark L. Welton Professor and Chief of General Surgery at Stanford University. Kebebew is internationally known for his clinical and research expertise in endocrine surgery and oncology.
Soma Sengupta is a British-American and a specialty board certified neuro-oncologist board certified Neurologist. She is an Associate Professor of Neurology and Rehabilitation Medicine at the University of Cincinnati, with appointments in Cancer Biology and Neurosurgery. She is also affiliated with Cincinnati Children's Hospital Medical Center.
